| Filed On | Filing |
|---|---|
| 21 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Two Late-Stage Platforms Targeting Inflammation- Driven Disease Corporate Presentation October 2026 NASDAQ: INMB |
| 23 Sep 2026 |
Form 4: Clark Ronnie Duane, Director
Granted 100,000 Stock Options |
| 23 Sep 2026 |
Form 3: Clark Ronnie Duane, Director
No securities owned |
| 17 Sep 2026 |
Form 4: Sapirstein James, Director
Granted 100,000 Stock Options |
| 16 Sep 2026 |
Form 3: Sapirstein James, Director
No securities owned |
| 14 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization |
| 06 Aug 2026 | QUARTERLY REPORT |
| 31 Jul 2026 | 8-K: Other Events |
| 07 Jul 2026 |
Form 4: Juda Scott, Director
Received 14,801 shares by exercise or conversion ($20.7K) · Exercised 14,801 Common Stock Purchase Warrant ($1.85K) |
| 07 Jul 2026 |
Form 4: Lowdell Mark William, Chief Scientific Officer
Received 7,211 shares by exercise or conversion ($10.1K) · Exercised 7,211 Common Stock Purchase Warrant ($901) |
| 07 Jul 2026 |
Form 4: Moss David J, Director
Received 9,014 shares by exercise or conversion ($12.6K) · Exercised 9,014 Common Stock Purchase Warrant ($1.13K) |
| 01 Jul 2026 | 8-K: Entry into a Material Definitive Agreement |
| 23 Jun 2026 | 8-K: Other Events |
| 17 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders |
| 02 Jun 2026 | 8-K: Other Events |
| 14 May 2026 | 8-K: Other Events |
| 07 May 2026 | QUARTERLY REPORT |
| 05 May 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 23 Apr 2026 |
Proxy statement: annual meeting on June 16, 2026
CEO pay $1.8M, down 32% |
| 30 Mar 2026 | ANNUAL REPORT |
Loading...
